Impact of adherence to ibrutinib on clinical outcomes in real-world patients with chronic lymphocytic leukemia-Reference-Cited by-同舟云学术

Impact of adherence to ibrutinib on clinical outcomes in real-world patients with chronic lymphocytic leukemia

Published:2022-03-06 Issue:8 Volume:63 Page:1823-1830
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Collins James¹,Stump Sarah E.²,Heiling Hillary³,Muir Michele¹⁴,Deal Allison³,Proco Darrian¹⁴,Nguyen Catharine¹,Cozad Monica¹,Mato Anthony²,Coombs Catherine C.⁵,Muluneh Benyam¹³

Affiliation:

1. UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA

2. Memorial Sloan Kettering Cancer Center, New York, NY, USA

3. UNC Lineberger Cancer Center, Chapel Hill, NC, USA

4. GlaxoSmithKline, Research Triangle Park, NC, USA

5. Department of Medicine, University of North Carolina, Chapel Hill, NC, USA

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2022.2045597

Reference37 articles.

1. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial

2. B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells

3. Mutation of Unique Region of Bruton's Tyrosine Kinase in Immunodeficient XID Mice

4. Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment adherence and adverse event management in chronic lymphocytic leukemia: challenges and strategies for the future;Expert Review of Clinical Pharmacology;2024-04-25

2. Key Performance Indicators and Metrics for the Implementation of an Oral Chemotherapy Adherence Program;Journal of the National Comprehensive Cancer Network;2024-04

3. Results from a Real-World Multicenter Analysis of 482 Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Look at Racial Differences;Targeted Oncology;2023-09

4. Real-World Comparison of First-Line Treatment Adherence Between Single-Agent Ibrutinib and Acalabrutinib in Patients with Chronic Lymphocytic Leukemia;Patient Preference and Adherence;2023-08

5. Adherence to ibrutinib remains an unmet clinical need in chronic lymphocytic leukemia;Leukemia & Lymphoma;2022-06-15